Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interview: Head Of Turkish Industry Body Highlights Key Challenges In 2019

Executive Summary

Production localization and the fixed rate set for the euro against the lira will be key topics for the pharma industry in Turkey this year, with the expected further devaluation of the domestic currency likely to inflict more damage on companies. Turgut Tokgöz, secretary general of the Turkish industry association, spoke to Scrip.

You may also be interested in...



Localization Barriers To Trade In Medicines And Health Care Products: The Tricky Business Of Balancing Competing Interests

There is a clear tension at a global level between the need for the international movement of pharmaceutical products and the need for access to affordable medicines to support a sustainable health care system. Lincoln Tsang examines the global environment and suggests it is something that the British medicines and health care products industries will need to bear in mind when considering the prospect of the UK leaving the EU under WTO terms, as some are advocating.

Turkey’s New Fixed Euro Rate Spells More Pressure For Industry

The Turkish government has set the fixed Euro rate to calculate drug prices at TRY3.40 for 2019.

Political Turmoil, Big Pharma Resistance Threaten Turkey's Drug Production Drive

The Turkish government's drive to increase domestic production of medicines used the country has had some success for generic drugs, but it looks like the authorities may have given up hope when it comes to high-value products.

Topics

UsernamePublicRestriction

Register

SC124886

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel